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Background
Combination therapy with deferipron and desferrioxa-
mine (DFP+DFO) seems more effective than DFP and
DFO in monotherapy in removing myocardial iron.
However, no data are available in literature about pro-
spective comparisons on cardiac iron and function in
TM patients treated with DFP+DFO versus DFP and
DFO in monotherapy. Aim: The aim of this multi-centre
study was to assess prospectively in a large clinical set-
ting the efficacy of the DFP+DFO versus DFP and DFO
in TM patients by quantitative MR.
Methods
Among the first 739 TM patients enrolled in the MIOT
(Myocardial Iron Overload in Thalassemia) network,
253 patients performed a MR follow up study at 18±
3 months according to the protocol. We evaluated pro-
spectively the 43 patients treated with DFP+DFO versus
the 30 patients treated with DFP and the 66 patients
treated with DFO between the 2 MR scans. Myocardial
iron concentrations were measured by T2* multislice
multiecho technique. Biventricular function parameters
were quantitatively evaluated by cine images.
Results
Excellent/good levels of compliance were similar in the
3 groups (DFP+DFO 91% versus DFP 97% versus DFO
92%; P =0.76). Among the patients with no significant
myocardial iron overload (MIO) at baseline (global heart
T2*[[Unsupported Character - &#61619;]]20 ms), there
were no significant differences between groups to main-
tain the patients without MIO (DFP+DFO 90% versus
DFP 100% versus DFO 100%; P=0.053). Among the
patients with MIO at baseline (global heart T2*<20 ms),
in all groups there was a significant improvement in the
global heart T2* value (DFP+DFO P=0.0001, DFP
P=0.001 and DFO P=0.003), in the number of segment
with a normal T2* value (DFP+DFO P=0.0001, DFP
P=0.031, DFO P=0.0001) and in the right global systolic
function (DFP+DFO P=0.002, DFP P=0.031, DFO
P=0.045). The improvement in the global heart T2* was
significantly different among groups (mean difference
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DFO 3.6±5.4; P=0.009). The improvement in the global
heart T2* was significantly higher in the DFP+DFO ver-
s u st h eD F Og r o u p( P = 0 . 0 1 7 ) ,b u ti tw a sn o ts i g n i f i -
c a n t l yd i f f e r e n ti nt h eD F P + D F Ov e r s u st h eD F Pg r o u p
(P=0.36) (see figure). The changes in the global systolic
bi-ventricular function were not significantly different
among groups.
Conclusions
Prospectively in a large clinical setting over 15 months
in TM patients combined therapy DFP+DFO confirmed
superior reduction in myocardial iron in comparison to
DFO, but no significant differences were found versus
DFP monotherapy.
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